SPG 302
Alternative Names: SPG-302Latest Information Update: 25 Jun 2024
At a glance
- Originator Spinogenix
- Developer Novotech; Spinogenix
- Class Benzene derivatives; Benzothiazoles; Ethylene glycols; Neuroprotectants; Small molecules
- Mechanism of Action Synaptic transmission modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Amyotrophic lateral sclerosis
Most Recent Events
- 20 Jun 2024 Australia Human Research Ethics Committee approves regulatory application for SPG 302 in Alzheimer's disease
- 04 Jun 2024 Spinogenix plans a phase II trial for Schizophrenia (In adults), in July 2024 (NCT06442462)
- 29 May 2024 US FDA clears the investigational new drug (IND) application for SPG 302 in Amyotrophic lateral sclerosis